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Abstract
The involvement of the MET oncogene in de novo and acquired resistance of non-small cell lung
cancers (NSCLC) to tyrosine kinase inhibitors (TKIs) has been reported, but the precise
mechanism by which MET overexpression contributes to TKI-resistant NSCLC remains unclear.
MicroRNAs (miRNAs) negatively regulate gene expression and their dysregulation has been
implicated in tumorigenesis. To understand the role of microRNAs in TKI-resistant NSCLC, we
examined TK receptor-mediated microRNA changes. Here we report that miR-30b/c and
miR-221/222, modulated by both EGF and MET receptors, and miR-103, -203, controlled only by
MET, play important roles in gefitinib-induced apoptosis and epithelial-mesenchymal transition
(EMT) of NSCLC cells, in vitro and in vivo, by inhibiting the expression of Bim, APAF-1, PKC-ε
and SRC genes. The finding suggests that modulation of specific microRNAs may provide a
therapeutic approach for future treatment of NSCLC.
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tMicroRNAs repress gene expression by inhibiting mRNA translation or by promoting
mRNA degradation and are considered master regulators of different processes, ranging
from proliferation1 to apoptosis2. Altered miRNA expression in various human tumor types
has been observed, and critical roles of miRNAs in cancer pathogenesis and response to
therapy have been demonstrated 3,4. Non-small cell lung cancers (NSCLC) account for
roughly 85% of all lung cancer cases5. Although NSCLC is a remarkably heterogeneous
disease that includes distinct morphological and molecular subtypes, activation of epidermal
growth factor receptor (EGFR) and MET (the receptor tyrosine kinase (RTK) for hepatocyte
growth factors) is common and associated with RAS/ERK and PI3K/AKT axes stimulation,
leading to NSCLC cell proliferation, survival and invasion6. Tyrosine kinase inhibitors
(TKI) gefitinib and erlotinib effectively target EGFR in NSCLC patients, but these
important therapeutic agents are ultimately limited by the emergence of drug resistance
mutations and other putative molecular mechanisms.7
MET protein expression and phosphorylation have been associated with primary and
acquired resistance to EGFR TKI therapy in NSCLC patients 8,9, strongly implicating MET
as an effective therapeutic target to overcome resistance to this important class of drugs in
lung cancer10. Here we show that EGF and MET receptors, by modulating specific
microRNAs, control gefitinib-induced apoptosis and NSCLC tumorigenesis. Our results are
the first to identify EGF and MET receptor-regulated microRNAs representing oncogenic
signaling networks in NSCLC.
Results
MicroRNAs modulated by both EGFR and MET
To identify EGFR- and MET-regulated-miRNAs, we stably silenced EGFR and MET in
Calu-1 cells using shRNA lentiviral particles (Fig. 1a) and examined global microRNA
expression profiles. In EGFR- and MET-knockdown (EGFR-KD and MET-KD) Calu-1
cells, 35 and 44 significantly dysregulated microRNAs were identified, respectively (Figs.
1b and Supplementary Fig. 1a). MicroRNAs with >1.5- (EGFR) and with >1.7- (MET) fold-
change are shown. By comparing the two lists, only 8 microRNAs were found to be
regulated by both EGFR and MET (Fig. 1c): miR-21 (fold changeEGFR-KD= -1.56; fold
changeMET-KD= -1.7), -221/222 (f.c.EGFR-KD= -1.79/-1.66; f.c.MET-KD= -2.07/-1.75), -30b/c
(f.c.EGFR-KD= -1.81/-2.4; f.c.MET-KD= -3.5/-4.0), -29a/c (f.c.EGFR-KD= -1.52/-1.53;
f.c.MET-KD= -1.72/-1.79), and -100 (f.c.EGFR-KD= -1.55; f.c.MET-KD= -1.72). We initially
focused on miR-30b/c and 221/222, downregulated after both MET and EGFR silencing and
showing the highest expression level fold-change. We also investigated two microRNAs
most differentially induced after MET silencing, miR-103 (f.c.= 2.45) and miR-203 (f.c.=
2.5), based on recent evidence for MET overexpression in de novo and acquired resistance
to TKIs8,9. Expression levels of these six miRNAs in EGFR-KD and MET-KD Calu-1 cells
were validated using qRT-PCR (Supplementary Fig. 1b) and northern blot (Fig. 1d) analysis.
MiR103, 203, 30b/c and 221/222 target PKCε, SRC, BIM and APAF1
As MET and EGFR RTKs play a significant role in lung cancer tumorigenesis and
progression11, we hypothesized that miR-103 and miR-203 (increased after MET
knockdown) are tumor suppressors and miR-221/222 and miR-30b/c (decreased after MET
and EGFR silencing) are oncogenic. Our search for mRNA targets of miR-103, -203,
-221/222, and -30b/c using Targetscan and Pictar computational tools revealed that 3′UTRs
of human Apaf-1, BIM, Pkc-ε and Src genes contain evolutionarily conserved binding sites
specific for these miRNAs (Supplementary Fig. 2a). We focused on these genes based on
their role in TKI sensitivity (BIM and APAF-1)12,13 and resistance (SRC)14 or negative
allosteric modulation of EGFR signalling (PKC-ε)15. To investigate whether these miRNAs
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tdirectly interact with the four putative target genes, we cotransfected pGL3-3′UTR vectors
with synthetic miR-103, -203, 221/222 and -30b/c. Decreased luciferase activity indicated
direct miR-PKC-ε, SRC, APAF-1 and BIM 3′ UTR interactions (Fig. 1e), and target gene
repression was rescued by mutations or deletions in the complementary seed sites (Figs. 1e
and Supplementary Fig. 2a). Western blot analysis showed an inverse correlation (p<0.05)
between miR-221/222, -103, -203, 30b/c expression and target protein amount in a NSCLC
cell panel (Supplementary Fig. 2b,c) confirmed by Pearson coefficient (Figs. 1f and
Supplementary Fig. 2d). The immunoblot analysis fully agreed with data obtained using
reporter gene assays (Supplementary Results, Figs. 1g–j and Supplementary Fig. 3a,b).
Detection of PKC-ε, SRC, APAF-1, BIM proteins in vivo in 110 lung cancer specimens
using miRNA in situ hybridization (ISH) followed by immunohistochemistry (IHC) further
strengthened the negative correlation between these proteins and miR-103, -203, 221/222
and -30b/c seen in vitro (Supplementary Table 1). An inverse correlation between miR-203/
SRC, miR-30c/BIM, miR-103/PKC-ε, and miR-222/APAF-1 expression was observed in
the majority of the lung cancer tissues (Supplementary Fig. 4a,b). Moreover, MET
overexpression was seen in 52% (57/110) of the same 110 lung tumor samples
(demonstrated using miRNA ISH/MET IHC; Supplementary Fig. 5a), low miR-103 and
miR-203 expression and high miR-222 and miR-30c expression was observed in MET-
overexpressing tumors (Fig. 2a; Supplementary Fig. 5a). Interestingly, the majority of MET
overexpressing tumors had accompanying metastases (Supplementary Fig. 5b), indicating
that MET-regulated microRNAs play a role in metastatic spread of lung cancer cells.
We extended our analysis to 40 independent lung tumors with annotated clinical history
(Supplementary Table 2), divided into two groups of “low” and “high” MET and EGFR
expression (based on qRT-PCR; Supplementary Fig. 5c). ANOVA confirmed that miR-30b-
c and miR-221-222 were differentially expressed between the two groups, whereas Pearson
coefficient identified an inverse correlation MET-miR-103, -203 (Fig. 2b,c). The qRT-PCR
results were corroborated using IHC analysis for MET and EGFR (Supplementary Fig. 5d).
In addition, MET overexpression was observed in tumors that presented distant metastases
versus non-metastatic cases and there was no correlation between metastases and EGFR
expression in these 40 lung cancers (Fig. 2d and Supplementary Fig. 5e).
MiR-30b-c, 221-222, 103, 203 regulate gefitinib sensitivity
Having demonstrated that EGFR regulates miR-221-222 and miR-30b-c, we investigated a
role for these miRs in gefitinib-induced apoptosis in NSCLC with wild-type EGFR (Calu-1
and A549 cells) versus EGFR exon 19 deletions (PC9 and HCC827). Calu-1 and A549 cells
were completely resistant to all concentrations of gefitinib tested (up to 20 μM); in contrast,
PC9 and HCC827 EGFR-mutant cells were significantly growth-inhibited even by low (0.1
μM) dose gefitinib (Fig. 3a), in agreement with a previous study16. Interestingly, after
gefitinib treatment, marked miR-30b-c and -221-222 downregulation and increased BIM and
APAF-1 protein levels were observed, but only in PC9 and HCC827 sensitive cells (Fig.
3b,c). Moreover, as previously anticipated16, the level of phosphorylated ERKs was
markedly decreased in Hcc827 and PC9 but not in Calu-1 cells versus untreated cells (Fig.
3c).
To directly assess the relevance of miR-30b-c and -221-222 in gefitinib-induced apoptosis,
we analyzed expression levels of these miRNAs in PC9 GR and HCC827 GR, NSCLC cells
with acquired gefitinib resistance, obtained after long-term exposure to increasing drug
concentrations8,17. In contrast to the gefitinib-responsive parental cells, decreased miR-30b-
c and -221/222 expression and modulation of their relative targets were not observed (Fig.
3d; Supplementary Fig. 6a). Also of note, miR-30c and miR-221/222 overexpression in
gefitinib-sensitive HCC827 and PC9 rendered these cells less drug responsive (Figs. 4a and
Supplementary Fig. 7a), and knockdown of miR-30b-c and -221-222 increased gefitinib
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tsensitivity of Calu-1, HCC827GR and PC9GR (Figs. 4a and Supplementary Fig. 7b),
indicating that these miRs are important modulators of TKI resistance.
To investigate the contribution of miR-30b-c and 221-222-mediated APAF-1 and BIM
downregulation to cellular TKI response, we overexpressed APAF-1 and BIM in A549
resistant cells. Gefitinib-induced PARP cleavage was observed in cells overexpressing BIM
and APAF-1 but not in cells transfected with an empty vector plasmid (Fig. 4b). Conversely,
response to gefitinib was reduced by BIM and APAF-1 silencing in gefitinib-sensitive
HCC827 and PC9 cells (Fig. 4c). We cloned wild type and mutated 3′UTRs of BIM and
APAF-1 (used for luciferase assays, Fig. 1e) downstream of BIM and APAF-1 coding
sequences and performed caspase 3/7 and viability assays. No increase in cell death was
observed after gefitinib treatment of A549 cells cotransfected with wild type 3′ UTRs for
BIM and APAF-1 and miR-30b-c and -221-222; conversely, miR binding site mutation or
deletion restored the apoptotic response to gefitinib, suggesting that the effect of APAF-1
and BIM on gefitinib sensitivity was directly related to miR-30b-c and -221-222-mediated
knockdown of these proteins (Figs. 4d and Supplementary Fig. 7c).
Because miR-30b-c and -221-222 are also regulated by MET, we hypothesized that MET
inhibition, by modulating these miRs in common with the EGFR pathway, could overcome
gefitinib-resistance in NSCLC. In support of this hypothesis, strong downregulation of
miR-30b-c and -221-222 was observed in Calu-1- and A549-MET overexpressing cells (data
not shown) treated with SU11274 MET inhibitor or MET knockdown (Supplementary Fig.
8a,b). Moreover, increased caspase 3/7 activity and decreased cell viability were observed in
SU11274-treated Calu-1 or Calu-1-MET-KD cells exposed to different gefitinib
concentrations. (Supplementary Fig. 8c,d). Taken together, these results suggest that MET
inhibition restores gefitinib sensitivity in TKI-resistant Calu-1 cells through the
downregulation of miR-30b-c and miR-221-222.
Other miRNAs commonly modulated by EGFR-MET, including miR-21, miR-29a/c and
miR-100 (Fig. 1c) were downregulated in HCC827- and PC9-gefitinib treated cells and
found involved in the response to the drug (Supplementary Results, Supplementary Figs. 9,
10 and 11).
Next, we focused on miR-103 and -203, strongly upregulated after MET knockdown in
Calu-1 cells (Fig. 1d). As expected, treatment of Calu-1 cells with SU11274 increased
(P<0.05) miR-103 and -203 expression (Supplementary Fig. 12a). SRC and PKC-ε exert
pro-survival effects and contribute to gefitinib resistance by activating AKT and ERK
signaling pathways14,15. Accordingly, miR-103 and -203-overexpression in A549 cells was
associated with reduced phosphorylation of AKT and its substrate GSK3β and ERKs
(Supplementary Fig. 13a). Engelman et al. previously reported that MET induces gefitinib
resistance through persistent PI3K/AKT and ERK signaling activation8, and our results
indicate that MET overexpression controls gefitinib resistance through activation of the
AKT/ERKs pathway, mediated at least in part by miR-103 and -203. In agreement with
Engelman et al., enforced expression of miR-103, -203 or Pkc-ε and Src silencing increased
Calu-1 cell sensitivity to gefitinib (assessed by caspase 3/7 and viability assays,
Supplementary Fig. 13b,c). Importantly, we found that miR-103 and -203 decreased and
SRC and PKC-ε expression consequently increased in HCC827 GR cells with acquired
MET amplification and gefitinib resistance8, corroborating our hypothesis that MET
controls the response to TKIs, at least in part through miR-103 and -203 and their respective
targets (Supplementary Fig. 13d,e). Finally, to analyze the sensitivity to gefitinib in vivo, we
stably transfected A549 cells with GFP-lentivirus constructs containing either full-length
miR-103, miR-203 or anti-miR-221 and -30c. MiR-103 and miR-203 overexpression or
miR-221 and -30c knockdown resulted in dramatic tumor growth inhibition and increased
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tsensitivity to gefitinib-induced apoptosis in nude mice after two weeks of treatment (Figs.
4e,f and Supplementary Fig. 14a). MiR-221-222 down-regulation and miR-103, -203
upregulation in the xenograft tumors were confirmed by qRT-PCR (Supplementary Fig.
14b).
MiR-103 and -203 reduce NSCLC cell migration and proliferation
The anti-proliferative activity of miR-103 and -203 in different cancers has been previously
reported18,19,20. To further investigate the functional role of miR-103 and miR-203 in
NSCLC tumorigenesis, we assessed the impact of miR-103 and -203 gain of function or loss
of PKC-ε and SRC on cell migration and cell cycle kinetics. Migration was reduced (by 2-
fold compared to controls) in cells with increased miR-103 and -203 or decreased PKC-ε
and SRC expression (Fig. 5a). These results were further confirmed by wound-healing assay
(Fig. 5b). In addition, A549 and Calu-1 cells transfected with miR-103, -203 or Pkc-ε and
Src siRNAs showed increased G1 cell fraction and a corresponding decreased number of
cells in S and G2-M phases, with miR-203 and siSRC having a slightly stronger effect
compared to miR-103 and siPKC-ε (Fig. 5c).
MiR-103, 203 promote mesenchymal-to-epithelial transition
An association between EMT and development of chemoresistance, including resistance to
EGFR targeted therapy, leading to recurrence and metastasis has recently been reported21.
Although identifying the molecular events underlying EMT is an intense area of
investigation, what triggers the onset of EMT in tumor cells remains a mystery. We
observed a striking change in cellular shape in MET-KD Calu-1 cells from spindle-,
fibroblastoid morphology to an epithelial polarized phenotype upon MET-KO (Fig. 6a),
prompting us to further investigate whether this morphological change could be due to a
mesenchymal-to-epithelial transition. We assessed the expression of key EMT transition-
associated markers and observed decreased expression of mesenchymal markers and
increased E-cadherin expression (Fig. 6b,c.d), strongly indicating reversion of Calu-1 cells
to an epithelial phenotype after MET knockdown. Importantly, in MET-KD cells, Snail
protein expression was lower, localized to the cytoplasm (Fig. 6b) and presumably
nonfunctional22. It is worth noting that a morphological change in EGFR-KD Calu-1 cells
was not observed, and miR-200c23,24,-103 and -203 were not upregulated (Supplementary
Fig. 1a). To test if miR-103 and -203 were involved in mesenchymal-epithelial transition,
we overexpressed these miRs in Calu-1 cells and observed downregulation of several
mesenchymal markers and increased E-cadherin expression, indicating a role for these miRs
in the mesenchymal-epithelial transition (Fig. 6e–g; Supplementary Fig. 15a,b). Moreover,
PKC-ε and SRC silencing increased E-cadherin and decreased SNAIL, ZEB1, ZEB2 (zinc
finger E-box binding 2), vimentin and fibronectin mRNA levels (Supplementary Fig. 15c).
Since it has been recently reported that miR-103 targets Dicer25, we investigated the effects
of Dicer knockdown on tumorigenesis and gefitinib-induced apoptosis of NSCLC.
Remarkably, almost complete Dicer knockdown reduced not only gefitinib resistance but
also migration and the expression of mesenchymal markers of NSCLC cells, suggesting that
miR-103 could be involved in the mesenchymal-epithelial transition process also through
Dicer downregulation (Supplementary Results and Supplementary Fig. 16). In conclusion,
by regulating expression of specific miRs, MET orchestrates the convergence of several
EMT-associated pathways, including Dicer, SRC, PKC-ε and AKT pathways, supporting
the possibility that MET targeting could provide a realistic strategy to control EMT and
NSCLC progression.
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Although initially promising, it is now clear that EGFR inhibitors, including gefitinib and
erlotinib, will not cure the majority of NSCLC patients, even in those cancers expressing
mutant EGFR. Therefore, a more complete understanding of how these drugs work and the
downstream molecular mediators of EGFR will provide critical information to help design
strategies to augment their efficacy.
In previous work, we identified MET as a regulator of miR-221-222 expression3. To better
understand the pathway(s) involved in NSCLC tumorigenesis and drug resistance, we
investigated microRNAs modulated by EGFR and MET tyrosine kinases. We focused on
miR-30b-c and miR-221-222, regulated by both EGFR and MET, and miR-103, -203,
regulated by MET only. We show that gefitinib treatment, by inducing miR-30b-c and
221-222 downregulation and consequent up-regulation of APAF-1 and BIM, previously
reported to play a fundamental role in gefitinib-induced apoptosis12, triggers programmed
cell death in sensitive Hcc827 and PC9 cells but not in resistant Calu-1 and A549 cells.
More importantly, downregulation of miR-30b-c and -221-222 was not seen after gefitinib
treatment in the resistant clones (HCC827 GR and PC9GR) of gefitinib hypersensitive
EGFR exon 19 mutant HCC827 and PC9 NSCLC cell lines. We demonstrate that this
resistance could be overcome by MET inhibitors, which downregulate miR-30b-c and
221-222 and sensitize NSCLC to gefitinib or by anti-miR-221-222 and anti-30c, which
strongly increase gefitinib-sensitivity in xenograft models in vivo.
PTEN loss, by partially uncoupling mutant EGFR from downstream signaling and activating
EGFR, contributes to erlotinib resistance26. Previously, we found PTEN to be a
miR-221-222 target3, making it reasonable to speculate that these two microRNAs play a
role in gefitinib-resistance of NSCLC cells, not only through APAF-1 but also through
PTEN-regulation. Notably, overexpression of another miR targeting PTEN27,28, miR-21,
induced gefitinib resistance in HCC827 and PC9 sensitive cells. We also demonstrate that
miR-103 and -203, up-regulated after MET silencing or treatment with the MET inhibitor
SU11274, induce apoptosis in gefitinib-resistant NSCLC, reduce mesenchymal markers and
increase epithelial cell junction proteins, by downregulating expression of PKC-ε, SRC and
Dicer.
Remarkably, EMT has recently been shown to play a role in acquired resistance to gefitinib
in A549 cells, indicating that mesenchymal status is related to “inherent resistance” to
gefitinib or erlotinib in NSCLC29. As proposed in the model in Fig. 6h, either MET
knockdown or inhibition of MET activity, through up-regulation of miR-103, miR-203,
miR-200c30 and the down-regulation of miR-221-222 and miR-30b-c induces gefitinib
sensitivity, motility inhibition and mesenchymal-epithelial transition in NSCLC. The
identification of prognostic and predictive factors associated with sensitivity or resistance to
anti-EGFR agents is a key area of investigation, and aberrant key signaling proteins,
including RAS/MEK, AKT/mTOR and MET kinase, have recently been recognized as
critical targets8. As activation or amplification of MET signaling contributes to TKI
resistance through multiple independent mechanisms and leads to rapid evolution of drug
resistance, stratifying NSCLCs based on MET expression may allow for individualization of
patient tumors. Such a strategy has the potential to increase treatment efficacy by
eliminating unnecessary side effects in NSCLC patients who would not benefit from a
particular therapeutic regimen.
It has recently been reported that circulating microRNAs in NSCLC patients may represent a
noninvasive strategy for predicting drug response, preventing over-diagnosis and -treatment
of low-risk disease, allowing for early disease detection in high-risk subjects, and avoiding
Garofalo et al. Page 6
Nat Med. Author manuscript; available in PMC 2012 October 09.
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
t
N
I
H
-
P
A
 
A
u
t
h
o
r
 
M
a
n
u
s
c
r
i
p
tearly metastatic disease31. Noninvasive approaches may be particularly significant because
not all the persons with lung cancer have operable disease and tumor tissue is not available
for genetic analysis. In this regard, in human primary lung tumors, we identified expression
of miR-103,-203,-30b-c and -221-222 as prognostic markers. Our data indicate that analysis
of miR-103, miR-203, miR-30b-c and miR-221-222 expression levels, and also of miR-21
and -29a, 29c, miR-100 after initial treatment with TKIs or MET inhibitors, may potentially
provide a noninvasive strategy for predicting response to those inhibitors. The possibility of
using these miRNAs as serologic markers for lung cancer warrants further study, supported
by recent findings identifying miR-221-222 and -21 as potential blood-based biomarkers
with diagnostic value in NSCLC patients32,33. In addition, our clinical validation studies on
lung tumor specimens reveal that MET overexpression and consequent absence of miR-103
and -203 may be used to identify primary lung tumors with metastatic capacity. Indeed,
reduced expression of miR-103 and -203 could be predictive of more aggressive, early
metastatic tumors. Finally, our results using a tumor xenograft model support a novel
therapeutic approach based on modulation of these microRNAs by RNA-based therapeutics,
which may represent a clinically useful modality to treat TKI resistance in NCSLC patients
with or without MET overexpression.
Methods
TaqMan Array MicroRNA Cards
For RNA extraction, see the Extended Experimental Procedures. The TaqMan Array Human
MicroRNA Card (Applied Biosystem) Set v3.0 is a two card set containing a total of 384
TaqMan MicroRNA Assays per card that enables accurate quantitation of 754 human
microRNAs. Included on each array is three TaqMan MicroRNA Assay, endogenous
controls to aid in data normalization and one TaqMan MicroRNA Assay not related to
human as a negative control. An additional preamplification step is enabled by Megaplex
PreAmp Primers, Human Pool Set v3.0 for situations where sensitivity is of the utmost
importance or sample is limiting.
In vivo experiments
Animal studies were performed according to institutional guidelines. A549 cells were stable
infected with a control miR, miR-103 and miR-203 or with anti-miR control, anti-miR-221
and anti-30c lentiviruses (SBI). 5×106 viable cells were injected s.c. into the right flanks of
6-wk-old male nude mice (Charles River Breeding Laboratories). Treatment started seven
days from tumor cell inoculation. Gefitinib was administered Monday through Friday for 2
weeks as oral gavage, at concentrations of 200 mg/kg in 1% Tween 80 (Sigma). in sterile
milli-Q water (vehicle control was 0.5% Tween 80 in sterile milli-Q water). Tumor size was
assessed twice per week by a digital caliper. The tumor volumes were determined by
measuring the length (l) and the width (w) and calculating the volume (V = lw2/2). 35 days
after injection, mice were sacrificed. Statistical significance between control and treated
animals was evaluated by using Student's t test. Animal experiments were conducted after
approval of the Institutional animal care and use committee, The Ohio State University.
Migration assay
Transwell insert chambers with 8-μm porous membrane (Greiner bio-one) were used for the
assay. Cells were washed three times with PBS and added to the top chamber in serum-free
media. The bottom chamber was filled with media containing 10% FBS. Cells were
incubated for 24 h at 37°C in a 5% CO2 humidified incubator. To quantify migrating cells,
cells on the top chamber were removed by using a cotton-tipped swab, and the migrated
cells were fixed in PBS, 25% glutaraldehyde and stained with Crystal Violet stain,
visualized under a phase-contrast microscope, and photographed. Cristal violet-stained cells
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twere moreover solubilized in acetic acid and methanol (1:1) and absorbance was measured
at 595 nm.
Immunofluorescence
Cells were grown on Labtek II-CC2 Chamber slides (Nunc), fixed with 4%
paraformaldehyde, and permeabilized with 0.2% Triton X-100/PBS prior blocking with 10%
sheep serum (Caltag Laboratories). All the primary antibodies were from Abcam. Secondary
antibodies were goat anti- mouse or -rabbit coupled to Alexa-488 (Invitrogen). F-actin was
stained by using phalloidin reagent (Invitrogen). Cell nuclei were visualized with DAPI
(Sigma). Slides were mounted with SlowFade Gold antifade reagent (Invitrogen).
Cell death and cell proliferation quantification
For detection of caspase 3/7 activity, cells were cultured in 96-well plates, in triplicate,
treated with gefitinib 5, 10, 15 μM and analyzed using Caspase-Glo 3/7 Assay kit (Promega)
according to the manufacturer's instructions. Continuous variables are expressed as mean
values ± standard deviation (s.d.). Cell viability was examined with 3-(4,5-
dimethylthiazol-2-yl)-2,5-dipheniltetrazolium bromide (MTS)-Cell Titer 96 AQueous One
Solution Cell Proliferation Assay (Promega), according to the manufacturer's protocol.
Metabolically active cells were detected by adding 20 μl of MTS to each well. After 1 h of
incubation, the plates were analyzed in a Multilabel Counter (Bio-Rad Laboratories).
Statistical analysis
Student's t test, one-way analysis of variance (ANOVA) and Fisher's exact test were used to
determine significance. All error bars represent the standard error of the mean. Pearson
correlation coefficient was calculated to test the inverse relation between miR-103,-203,
-221/222, -30b/c and their putative targets and between MET and miR-103, -203. Statistical
significance for all the tests, assessed by calculating p-value, was < 0.05.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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tFigure 1. MiR-221-222, 30b-c, 103, 203 target APAF-1, BIM, PKC-ε and SRC
(a) EGFR and MET proteins and mRNAs down-regulation after EGFR and MET silencing.
(b) Unsupervised hierarchical clustering based on miRNA expression profiles in shControl
versus shEGFR and shMET-Calu-1 cells at a p value <0.05. (c) Intersection of shEGFR and
shMET regulated microRNAs. (d) Northern blots showing miR-221,-222, 103, -203, -30b,
and -30c deregulation after MET knockdown. SnRNA U6, loading control. (e) Decreased
luciferase activity indicated direct miR-PKC-ε, SRC, APAF-1 and BIM 3′ UTR interactions
(Fig. 1e) and target gene repression was rescued by mutations or deletions in the
complementary seed sites. In the case of SRC only the site 1595-1601 is implicated in the
binding with miR-203; deletion of the site 1706-1712 did not rescue luciferase activity (See
also Supplementary Fig. 2). Relative repression of firefly luciferase expression was
standardized to a transfection control. (f) Inverse correlation between miR-103,-203,
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t221-222 and -30b-c and target proteins in a panel of NSCLC cells. Correlation coefficients
of -0.91 (miR-203/SRC), -0.92 (miR-221/APAF-1), -0.90 (miR-222/APAF-1), -0.55
(miR-30b/BIM), -0.91 (miR-30c/BIM), -0.87 (miR-103/PKC-ε), P<0.05. (g) MiR-221&222,
miR-30b-c overexpression decreased endogenous levels of APAF-1 and BIM. (h) MiR-103
and miR-203 overexpression decreased endogenous levels of PKC-ε and SRC. (i) Anti-
miR-221-222 and anti-miR-30b-c increased APAF-1 and BIM expression. (j) MET
knockdown induced APAF-1 and BIM upregulation and SRC and PKC-ε down-regulation.
Results are representative of at least, three independent experiments. Error bars depict ± s.d.
* P< 0.001, ** P< 0.05 by two tailed student's t test.
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tFigure 2. MiR-103-, 222-, 203-, 30c-MET co-expression analyses
(a) 110 lung cancer tissues were analyzed for miR-103, -222, -203, -30c expression by ISH
and then for MET by IHC. Upper row, from the left miR-103 signal (blue), MET (red) and
the mixed signal in which fluorescent yellow is indicative of miR and protein co-expression;
note the lack of miR-103 in presence of MET expression. In the serial section of the same
cancer (row below) one sees miR-222, the MET image and the co-expression of miR-222
and MET. Many cancer cells positive for miR-222 also express MET (yellow). The arrows
in the left panel (third row) depict benign stromal cells that express miR-203 (blue) and do
not express MET. Next panels represent MET (red) and the mixed signal. The arrow in the
fourth row depicts cancer cells positive for miR-30c; next panels depict MET signal and the
co-expression of miR-30c (yellow). Right panels show the RGB image of the ISH/lHC
reaction. (b) Box plots showing miR-30b-c, -221-222 expression in 40 lung cancer patients.
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tReal time PCR was used to classify tumors into two groups: EGFR-MET low and EGFR-
MET high by round function with the cut-off at 0.5 (2(-DeltaCt)). (See also Supplementary
Fig. 5). *P<0.0001 by Student's t test. (c) XY Scatter plots showing inverse correlation
between MET-103, MET-203. P<0.0001. (d) MET and EGFR immunostaining on 40 lung
tumor tissues. One representative case of 17 metastatic tumors expressing both MET and
EGFR is shown. Large arrow = tumor cells, small arrow = stroma. Scale bar, 100 μm.
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tFigure 3. Gefitinib downregulates miR-221-222 and 30b-c
(a) Calu-1, A549, PC9 and Hcc827 cells were treated with increasing concentrations of
gefitinib. Cell viability, relative to untreated controls, was measured after 24h. Each data
point represents the mean ± s.d. of five wells. (b) qRT-PCR showing miR-30b-c and
-221-222 down-regulation only in PC9 and Hcc827 gefitinib-sensitive cells and not in
Calu-1 and A549-resistant cells after treatment with 5 or 10 μM gefitinib. (c) PC9, Calu-1
and Hcc827 cells were treated for 24h with 5 or 10 μM gefitinib. An increase of BIM and
APAF-1 expression and a decrease of ERKs phosphorylation were observed only in the
Hcc827 and PC9 gefitinib-sensitive cells but not in the Calu-1 -resistant cells. β-actin was
used as loading control. (d) qRT-PCR showing that miR-30b-c and -221-222 expression did
not decrease in PC9 GR and HCC827GR cells (with acquired gefitinib resistance) exposed
to 10 μM gefitinib for 24h. All quantitative data were generated from a minimum of three
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treplicates. Error bars depict ± s.d. Two tailed student's t test was used to determine P values.
*P<0.001, **P<0.05.
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tFigure 4. MiR-30b-c, 221-222, 103, 203 regulates gefitinib sensitivity
(a) Parental and resistant HCC827 GR and PC9GR and Calu-1 cells treated with increasing
concentrations of gefitinib. Each data point represents the mean ± s.d of 6 wells. (b) Western
blot showing an increase in PARP cleaved fragment after BIM and APAF-1 over-expression
and gefitinib treatment (15μM) in A549 cells. (c) BIM and APAF-1 silencing in HCC827
and PC9 cells reduces the response to gefitinib. (d) Overexpression of miR-30b/c- and
-221/222-insensitive BIM and APAF-1 cDNAs, induces gefitinib sensitivity in A549 cells.
(e-f) MiR-103, -203 overexpression and miR-30c, -222 silencing increase gefitinib
sensitivity in vivo. (e) Growth curve of engrafted tumors and (f) comparison of engrafted
tumors in nude mice injected with A549 cells stable infected with anti-miR-control (ctr),
anti-30c, anti-221 and with miR-103 and -203 or an empty virus as control. The images
show average-sized tumors from among five of each category. In a, c, d and e error bars
indicate ± s.d. *P < 0.001, **P < 0.05 by two tailed student's t test.
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tFigure 5. MiR-103, 203 inhibit migration and proliferation of NSCLC
(a)Representative pictures of cells that migrated through the filter and stained with crystal
violet. Scale bar, 40μm. The results are means ± s.d, n=3. *P < 0.001. (b) Representative
photographs of scratched areas of confluent monolayer of A549 cells transfected with
miR-103, -203 or ctr miR at 0h and 24h after wounding with a pipet tip. Scale bar, 500 μm.
Significance values of *P< 0.00001 and **P<0.001 relative to miR scrambled transfected
cells. (c) Flow cytometric distributions of Calu-1 and A549 cells transfected with control
miR, miR-103, miR-203, control siRNA, PKC-ε and SRC siRNAs. The effect of miR-203
on cell cycle is slightly stronger than that of miR-103, as assessed by the ratio between Go-
G1 and S phases. (A549 G0-G1/S NT= 3.1±0.2; Src miR= 3.6±0.2; 103= 4.8±0.25; 203=
6.4±0.2; scr siRNA= 2.9±0.3; siPKC-ε= 4.8±0.1; siSrc= 5.7±0.25. Calu-1 G0-G1/S NT=
2.8± 0.34; Scr miR= 3.1± 0.21; 103= 4.3±0.25; 203= 6.3±0.25; Scr siRNA= 2.5±0.21;
siPKC-ε= 4.6±0.26; siSrc= 5.2±0.32). All quantitative values show mean ± s.d, n=5. Two
tailed student's t test was used to determine P values between G0-G1/S ratio. *P<0.00001
versus scr miR. **P<0.005 versus scr miR.
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tFigure 6. c-Met knockdown induces MET through miR-103 and -203
(a) Morphological changes of Calu-1 cells after MET knockdown. Scale bar indicates
20μm. (b) Immunofluorescence: Snail, mesenchymal intermediary filament vimentin and N-
cadherin in Calu-1 shControl and Calu-1 shMET. Snail expression is strong and nuclear in
Calu-1 ShCtr and is weaker and cytoplasmic in Calu-1 ShMET. Scale bar, 20μm. (c)
Western blots showing the downregulation of mesenchymal proteins as fibronectin,
vimentin and Snail and the upregulation of E-cadherin after MET knockdown in Calu-1
cells. Loading control, GAPDH. (d) qRT-PCR showing the expression of epithelial and
mesenchymal markers in Calu-1 ShCtr and Calu-1 shMET. (e) Immunofluorescence:
fibronectin, Snail and vimentin expression decreases after miR-103 or -203 overexpression
in Calu-1 cells. Scale bar indicates 20μm. (f) Immunofluorescence: E-cadherin increased
signal after miR-103 or -203 enforced expression in Calu-1 cells. Scale bar, 40μm. (g)
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tImmunoblot showing the down-regulation of mesenchymal markers after miR-103 or -203
overexpression. (h) A model is reported in which MET inhibition elicits upregulation of
miR-103 and -203, which in turn, downregulating PKC-ε, Dicer and SRC, induce gefitinib-
sensitivity and mesenchymal-epithelial transition (MET). MET knockdown induces also
miR-30b/c, -221/222 and -21 downregulation and consequent gefitinib-sensitivity through
BIM, APAF-1 and PTEN upregulation. EGFR knockdown decreases miR-221/222 and
-30b/c expression levels. In red are the up-regulated and in green the down-regulated miRs
after EGFR and MET silencing. Results are representative of at least four independent
experiments. P values were obtained by two-tailed student's t test. Error bars represent
standard deviation.
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